Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
52.66
+0.25 (0.48%)
At close: Jul 19, 2024, 4:00 PM
52.76
+0.10 (0.19%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 290 employees as of December 31, 2023. The number of employees increased by 80 or 38.10% compared to the previous year.
Employees
290
Change (1Y)
80
Growth (1Y)
38.10%
Revenue / Employee
$6,807
Profits / Employee
-$811,945
Market Cap
4.15B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 290 | 80 | 38.10% |
Dec 31, 2022 | 210 | 67 | 46.85% |
Dec 31, 2021 | 143 | 50 | 53.76% |
Dec 31, 2020 | 93 | 25 | 36.76% |
Dec 31, 2019 | 68 | 21 | 44.68% |
Dec 31, 2018 | 47 | 13 | 38.24% |
Dec 31, 2017 | 34 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Haemonetics | 3,657 |
Alkermes | 2,100 |
Ultragenyx Pharmaceutical | 1,276 |
Inspire Medical Systems | 1,011 |
ImmunityBio | 628 |
Axsome Therapeutics | 545 |
Avidity Biosciences | 253 |
CRNX News
- 3 days ago - Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 - GlobeNewsWire
- 11 days ago - Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner - GlobeNewsWire
- 5 weeks ago - Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly - GlobeNewsWire
- 6 weeks ago - Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D. - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts - GlobeNewsWire